GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Cannabinoid Technologies Holdings PLC (FRA:0CB) » Definitions » COGS-to-Revenue

Oxford Cannabinoid Technologies Holdings (FRA:0CB) COGS-to-Revenue : 0.00 (As of Oct. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Oxford Cannabinoid Technologies Holdings COGS-to-Revenue?

Oxford Cannabinoid Technologies Holdings's Cost of Goods Sold for the six months ended in Oct. 2023 was €1.35 Mil. Its Revenue for the six months ended in Oct. 2023 was €0.00 Mil.

Oxford Cannabinoid Technologies Holdings's COGS to Revenue for the six months ended in Oct. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Oxford Cannabinoid Technologies Holdings's Gross Margin % for the six months ended in Oct. 2023 was %.


Oxford Cannabinoid Technologies Holdings COGS-to-Revenue Historical Data

The historical data trend for Oxford Cannabinoid Technologies Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Cannabinoid Technologies Holdings COGS-to-Revenue Chart

Oxford Cannabinoid Technologies Holdings Annual Data
Trend May18 May19 May20 May21 Apr23
COGS-to-Revenue
- - - - -

Oxford Cannabinoid Technologies Holdings Semi-Annual Data
May19 Nov19 May20 Nov20 May21 Nov21 Oct22 Apr23 Oct23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only - - - - -

Oxford Cannabinoid Technologies Holdings COGS-to-Revenue Calculation

Oxford Cannabinoid Technologies Holdings's COGS to Revenue for the fiscal year that ended in Apr. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4.888 / 0
=

Oxford Cannabinoid Technologies Holdings's COGS to Revenue for the quarter that ended in Oct. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.352 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford Cannabinoid Technologies Holdings  (FRA:0CB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Oxford Cannabinoid Technologies Holdings's Gross Margin % for the six months ended in Oct. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.352 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Oxford Cannabinoid Technologies Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oxford Cannabinoid Technologies Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Cannabinoid Technologies Holdings (FRA:0CB) Business Description

Traded in Other Exchanges
Address
267 Banbury Road, Prama House, Oxford, GBR, OX2 7HT
Oxford Cannabinoid Technologies Holdings PLC is a pharmaceutical company engaged in cannabinoid drug development. The company uses a drug development that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Oxford Cannabinoid Technologies Holdings (FRA:0CB) Headlines

No Headlines